Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : IFx-Hu2.0,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : $15.0 million
Deal Type : Private Placement
Details : The proceeds will be used to fund the advancement of the combined company’s immunotherapy-focused development pipeline, including IFx-Hu2.0, designed to prime the activation of the immune system to target and attack tumor cells by making them look like...
Product Name : IFx-Hu2.0
Product Type : Vaccine
Upfront Cash : Undisclosed
May 23, 2023
Lead Product(s) : IFx-Hu2.0,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : $15.0 million
Deal Type : Private Placement
Lead Product(s) : CB5064 Analog
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, NIAID will be provided with CohBar's CB5064 Analogs to test in preclinical models of COVID-19, such as the golden Syrian hamster SARS-CoV-2 model.
Product Name : CB5064 Analog
Product Type : Peptide
Upfront Cash : Undisclosed
November 01, 2021
Lead Product(s) : CB5064 Analog
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : CB4211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 1b study is a randomized, double-blind, placebo-controlled evaluation of one dose level of CB4211 given once a day for four weeks in obese subjects with non-alcoholic fatty liver disease (NAFLD).
Product Name : CB4211
Product Type : Peptide
Upfront Cash : Inapplicable
April 21, 2021
Lead Product(s) : CB4211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CB4211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 1b study is a randomized, double-blind, placebo-controlled evaluation of one dose level of CB4211 given once a day for four weeks in obese subjects with non-alcoholic fatty liver disease (NAFLD).
Product Name : CB4211
Product Type : Peptide
Upfront Cash : Inapplicable
March 29, 2021
Lead Product(s) : CB4211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed,Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preclinical data shows that combination of a CB5138 Analog with nintedanib, the leading standard of care for treatment of Idiopathic Pulmonary Fibrosis (IPF), produced enhanced effects compared to nintedanib alone in mice.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
October 26, 2020
Lead Product(s) : Undisclosed,Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CB4211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Roth Capital Partners
Deal Size : $15.0 million
Deal Type : Public Offering
CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants
Details : CohBar intends to use the net proceeds from the offering, together with its existing cash resources, for general corporate purposes, funding preclinical and clinical development of its peptides, increasing working capital, operating expenses and capital ...
Product Name : CB4211
Product Type : Peptide
Upfront Cash : Undisclosed
August 25, 2020
Lead Product(s) : CB4211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Roth Capital Partners
Deal Size : $15.0 million
Deal Type : Public Offering
Lead Product(s) : CB4211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CohBar Resumes CB4211 Phase 1b Clinical Trial
Details : CohBar has resumed the Phase 1b stage of its Phase 1a/1b clinical trial of CB4211, its lead candidate for the treatment of nonalcoholic steatohepatitis (NASH) and obesity.
Product Name : CB4211
Product Type : Peptide
Upfront Cash : Inapplicable
July 07, 2020
Lead Product(s) : CB4211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MBT2
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CohBar Announces Acceptance of Late Breaking Abstract on its Antifibrotic Peptides
Details : The presentation highlights potential of MBT2 to Inhibit Fibrogenesis in Cultured Human Lung Cells and its efficacy in Mouse Models of Idiopathic Pulmonary Fibrosis (IPF).
Product Name : MBT2
Product Type : Peptide
Upfront Cash : Inapplicable
April 14, 2020
Lead Product(s) : MBT2
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CB4211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CohBar delays CB4211 Phase 1b Study for NASH and Obesity
Details : This delay is a result of a pause by some of the company’s clinical research organization partners in all of their activities related to the study in response to the COVID-19 pandemic.
Product Name : CB4211
Product Type : Peptide
Upfront Cash : Inapplicable
March 30, 2020
Lead Product(s) : CB4211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MBT2
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CohBar’s poster will contain data on a family of novel analogs of a peptide encoded in mitochondrial DNA, demonstrating beneficial effects in mouse models of Idiopathic Pulmonary Fibrosis (IPF).
Product Name : MBT2
Product Type : Peptide
Upfront Cash : Inapplicable
January 05, 2020
Lead Product(s) : MBT2
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable